First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

AIDS

Volumn 23, Issue 11, 2009, Pages 1367-1376

  Van Vonderen, Marit G A ^a,f   Lips, Paul ^a   Van Agtmael, Michiel A ^a   Hassink, Elly A M ^b   Brinkman, Kees ^c   Geerlings, Suzanne E ^d   Sutinen, Jussi ^e   Ristola, Matti ^e   Danner, Sven A ^a   Reiss, Peter ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Acquired immune deficiency syndrome; HIV; Nucleoside reverse transcriptase inhibitors bone mineral density; Osteoporosis

Indexed keywords

CALCIFEDIOL; CREATININE; DEOXYPYRIDINOLINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM METABOLISM; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MALE; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; OSTEOPOROSIS; PYRIMIDINONES; RITONAVIR; YOUNG ADULT; ZIDOVUDINE;

EID: 68449093191     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832c4947     Document Type: Article

References (37)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
2. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
3. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
4. Rivas P, Gorgolas M, Garcia-Delgado R, az-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008; 9:89-95.
5. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, Mira JA, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4:337-346.
6. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280.
7. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
8. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-481.
9. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91:2938-2945.
10. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HlV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
11. Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007; 23:1521-1530.
12. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278:48251-48258.
13. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-150.
14. Miller MG, Mulligan T. Human immunodeficiency virus and hypogonadal bone disease. Pharmacotherapy 2005; 25:632-634.
15. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277:19247-19250.
16. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
17. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/osteoporosis induced by highly active antiretroviral therapy for AIDS. Ann N Y Acad Sci 2006; 1068:297-308.
18. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
19. van Vonderen MGA, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, et al. ZDV/3TC/LPV/r, but not NVP/LPV/r, is associated with limb fat loss and relative abdominal fat accumulation after 24 months in antiretroviral-naive HIV-1 infected men in a randomized clinical trial (MEDICLAS) [Abstract]. 15th Conference on retroviruses and opportunistic infections; Boston, February 3-6, poster 937 2008.
20. Guglielmi G, Schneider P, Lang TF, Giannatempo GM, Cammisa M, Genant H K. Quantitative computed tomography at the axial and peripheral skeleton. Eur Radioi 1997; 7 (Suppl 2):S32 S42.
21. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
22. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS 2001; 15:703-709.
23. McComsey GA, Lo RV III, O'Riordan M, Walker UA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46:1290-1296.
24. Brown TT, McComsey G, King M, Qaqish R, Bernstein B, da Silva B. Bone mineral density 96 weeks after ART initiation: a randomized trial comparing Efavirenz-based therapy with a lopinavir/ritonavir-containing regimne with simplification to LPV/r monotherapy [Abstract]. 15th conference on retroviruses and opportunistic infections; Boston, 2008, abstract 966 2008.
25. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy R, et al. First-line Pl-containing regimens enhance decreased bone mineral density greater than NNRTI-containing regimen in HIV-1 infected patients: a substudy of the HIPPOCAMPE-ANRS 121 trial [Abstract]. 15th conference on retroviruses and opportunistic infections; Boston, 2008, abstract 967 2008.
26. Bolotin HH. A new perspective on the causal influence of soft tissue composition on DXA-measured in vivo bone mineral density. J Bone Miner Res 1998; 13:1739-1746.
27. Bolotin HH, Sievanen H, Grashuis JL. Patient-specific DXA bone mineral density inaccuracies: quantitative effects of nonuniform extraosseous fat distributions. J Bone Miner Res 2003; 18:1020-1027.
28. Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J, et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone 1995; 16:185-191.
29. Silva SAJr, Lopes Crisostomo LM, Olavarria V, Brites C, Galvao-Castro B. Alterations in bone mineral metabolism in Brazilian HIV-infected patients. AIDS 2003; 17:1578-1580.
30. Teichmann J, Stephan E, Discher T, Lange U, Federlin K, Stracke H, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism 2000; 49:1134-1139.
31. Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 1996; 52:63-98.
32. Manolagas SC. Role of cytokines in bone resorption. Bone 1995; 17 (2 Suppl):63S-67S.
33. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 1991; 10:15-21.
34. Panagakos FS, Hinojosa LP, Kumar S. Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha. Inflammation 1994; 18:267-284.
35. Jaeger P, Otto S, Speck RF, Villiger L, Horber FF, Casez JP, et al. Altered parathyroid gland function in severely immunocom-promised patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1994; 79:1701-1705.
36. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1259.
37. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-75.